Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference47 articles.
1. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer;Yang;N. Engl. J. Med.,2003
2. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer;Willett;Nat. Med.,2004
3. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients;Willett;J. Clin. Oncol.,2005
4. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis;Viloria-Petit;Cancer Res.,2001
5. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches;Kerbel;Cancer Metastasis Rev.,2001
Cited by 44 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Inhibition of galectins in cancer: Biological challenges for their clinical application;Frontiers in Immunology;2023-01-10
2. Glycomimetics for the inhibition and modulation of lectins;Chemical Society Reviews;2023
3. Simulating cellular galectin networks by mixing galectins in vitro reveals synergistic activity;Biochemistry and Biophysics Reports;2021-12
4. Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure;Cancers;2021-09-09
5. Dysbiotic stress increases the sensitivity of the tumor vasculature to radiotherapy and c-Met inhibitors;Angiogenesis;2021-02-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3